NHS expenditure could be cut with the launch of two Novartis biosimilars
Sandoz, a division of Swiss pharma giant Novartis, reveals that two of its biosimilars: Rixathon (biosimilar rituximab) and Erelzi (biosimilar etanercept) are now available in the UK for use in Europe. Both new medicines have proven to be non-inferior to their reference products, MabThera and Enbrel, respectively. Both products are approved in all the same